Evaluation of direct antiviral activity of the Deva-5 herb formulation and extracts of five Asian plants against influenza A virus H3N8

BMC Complementary and Alternative Medicine

Chimedtseren Chimedragchaa²  Jigden Baigalmaa⁴  Sanduijav Oldokh⁴  Galina A Danchinova³  Aleksander V Liapunov³  Janchiv Oyunbileg¹  Perenlei Molor-Erdene⁴  Maxim A Khasnatinov³  Namsrai Oyuntsetseg⁴ 

[1] National Centre for Public Health, Ministry of Health, Peace Avenue-17, Bayanzurkh district, Ulaanbaatar, Mongolia;Traditional Medical Science Technology and Production Corporation of Mongolia, Khan Uul district, Chinggis Avenue, Ulaanbaatar 17032, Mongolia;Federal State Public Institution Scientific Centre of Family Health and Human Reproduction Problems Siberian Branch of Russian Academy of Medical Sciences, K. Marks Str. 3, Irkutsk, Russian Federation;Institute of Traditional Medicine, Mongolian National University of Medical Sciences, Zorig str, Sukhbaatar district, Ulaanbaatar, Mongolia

关键词: Antivirals;    H3N8;    Influenza A virus;    Deva-5;    Terminalia chebula;    Polygonum bistorta;    Hypecoum erectum;    Momordica cochinchinensis;    Gentiana decumbens;   

Others  :  1087398
DOI  :  10.1186/1472-6882-14-235

 received in 2013-11-25, accepted in 2014-06-23,  发布年份 2014

【 摘 要 】

Background

The herb formulation Deva-5 is used in traditional medicine to treat acute infectious diseases. Deva-5 is composed of five herbs: Gentiana decumbens L., Momordica cochinchinensis L., Hypecoum erectum L., Polygonum bistorta L., and Terminalia chebula Retz. Deva-5 and its five components were investigated for in vitro antiviral activity against avian influenza A virus subtype H3N8.

Methods

The water extracts of the herbal parts of G. decumbens, H. erectum and P. bistorta, the seeds of T. chebula and M. cochinchinensis and Deva-5 were prepared by boiling and clarified by low-speed centrifugation and filtration. To assess the antiviral properties, avian influenza virus isolate A/Teal/Tunka/7/2010(H3N8) was incubated at 37°C for 30 min in the presence and absence of the extracts of five plants and DEVA-5 in various concentrations. Subsequently, the concentration of infectious virus in each sample was determined by plaque assays. Neutralisation indexes and 90% plaque reduction concentrations were estimated for each extract, and the significance of the data was evaluated using statistical methods.

Results

The extracts of G. decumbens, H. erectum, P. bistorta and Deva-5 demonstrated no significant toxicity at concentrations up to 2%, whereas extracts of T. chebula and M. cochinchinensis were well-tolerated by Madin-Darby canine kidney cells at concentrations up to 1%. The extracts of H. erectum, M. cochinchinensis and T. chebula reduced the titre of A/Teal/Tunka/7/2010 (H3N8) by approximately five-fold (p ≤ 0.05). The other three extracts did not significantly reduce the infectivity of the virus. The plaque reduction neutralisation tests revealed that none of the extracts tested were able to inhibit formation of plaques by 90%. However, three extracts, H. erectum, T. chebula and M. cochinchinensis, were able to inhibit formation of plaques by more than 50% at low dilutions from 1:3 to 1:14. The T. chebula extract had a concentration-dependent inhibitory effect.

Conclusions

For the first time, the consistent direct antiviral action of the extracts of H. erectum, T. chebula and M. cochinchinensis was detected. These extracts significantly reduced the infectivity of influenza A virus H3N8 in vitro when used at high concentrations (0.5–1%). However, Deva-5 itself and the remainder of its components did not exhibit significant antiviral action. The results suggest that H. erectum, T. chebula and M. cochinchinensis plants contain substances with direct antiviral activity and could be promising sources of new antiviral drugs.

【 授权许可】

   
2014 Oyuntsetseg et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Darmaa B, Burmaa , Naranzul T, Bayasgalan N, Enkhsaikhan D, Maitsetseg C, Nyama G, Tserendulam B, Enkhbaatar L, Gantsooj B, Urtnasan C, Nyamdavaa P: Influenza morbidity and surveillance results in Mongolia in 2010/2011 season. Mong J of Infect Dis Res 2011, 3(40):2-6.
• [2]Tong S, Li Y, Rivailler P, Conrardy C, Castillo DA, Chen LM, Recuenco S, Ellison JA, Davis CT, York IA, Turmelle AS, Moran D, Rogers S, Shi M, Tao Y, Weil MR, Tang K, Rowe LA, Sammons S, Xu X, Frace M, Lindblade KA, Cox NJ, Anderson LJ, Rupprecht CE, Donis RO: A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci 2012, 109(11):4269-74.
• [3]Webster RG, Bean WJ, Gorman OT, Chambers TM, Kawaoka Y: Evolution and ecology of influenza A viruses. Microbiol Rev 1992, 56(1):152-79.
• [4]World Health Organization: Summary of the 2011–2012 influenza season in the WHO European region. 2012. http://www.euro.who.int/__data/assets/pdf_file/0008/168866/Season-overview-2011-2012_9 Jul-2012_FINAL.pdf webcite
• [5]Guo Y, Wang M, Kawaoka Y, Gorman O, Ito T, Saito T, Webster RG: Characterization of a new avian-like influenza A virus from horses in China. Virology 1992, 188(1):245-55.
• [6]Yondon M, Heil GL, Burks JP, Zayat B, Waltzek TB, Jamiyan BO, McKenzie PP, Krueger WS, Friary JA, Gray GC: Isolation and characterization of H3N8 equine influenza A virus associated with the 2011 epizootic in Mongolia. Influenza Other Respir Viruses 2013, 7(5):659-65.
• [7]Tumurbaatar N: Hot-Natured Disorders in Traditional Mongolian Medicine. Volume 19. Ulaanbaatar: Eruul enkh press; 1998::92.
• [8]Manag rinchin junai: Traditional Medical source book. People's Republic of China: “Inner Mongolian medical treasurers” printing house; 1978:179.
• [9]Ligaa U, Davaasuren B, Ninjil N: Mongolian Medicinal Plants Using in Western and Eastern Medicine. Ulaanbaatar: JKC printing; 2005:121-122. 326, 438
• [10]Myagmar BE, Aniya Y: Free radical scavenging action of medicinal herbs from Mongolia. Phytomedicine 2000, 7:221-9.
• [11]Jung K, Chin YW, Yoon K, Chae HS, Kim CY, Yoo H, Kim J: Anti-inflammatory properties of a triterpenoidal glycoside from Momordica cochinchinensis in LPS-stimulated macrophages. Immunopharmacol Immunotoxicol 2013, 35:8-14.
• [12]Tsoi AY, Ng TB, Fong WP: Antioxidative effect of a chymotrypsin inhibitor from Momordica cochinchinensis (Cucurbitaceae) seeds in a primary rat hepatocyte culture. J Pept Sci 2005, 11(10):665-8.
• [13]Juthamas C, Kohei O, Hiroaki S, Ikuo S, Wichet L: Cochinin B, a Novel Ribosome-Inactivating Protein from the Seeds of Momordica cochinchinensis. Biol Pharm Bull 2007, 30(3):428-432.
• [14]Yinfen S, Shengkun L, Na L, Liling C, Jiwen Z, Junru W: Seven alkaloids and their antibacterial activity from Hypecoum erectum L. J Med Plants Res 2011, 5(22):5428-5432.
• [15]Deok SB, Young HK, Cheol HP, Chu WN, Javzan S, Jamyansan YA, Jae KL: Protopine reduces the inflammatory activity of lipopolysaccharide-stimulated murine macrophages. BMB Rep 2012, 45(2):108-113.
• [16]Duwiejua M, Zeitlin IJ, Waterman PG, Gray AI: Anti-inflammatory activity of Polygonum bistorta, Guaiacum officinale and Hamamelis virginiana in rats. J Pharm Pharmacol 1994, 46:286-90.
• [17]Anwesa B, Subir KB, Rabi RC: The development of Terminalia chebula Retz. (Combretaceae) in clinical research. Asian Pac J Trop Biomed 2013, 3:244-252.
• [18]Anwesa B, Subir KB, Premananda B, Nishith KP, Ranjan R, Rabi Ranjan C: Evaluation of antibacterial properties of Chebulic myrobalan (fruit of Terminalia chebula Retz.) extracts against methicillin resistant Staphylococcus aureus and trimethoprim-sulphamethoxazole resistant uropathogenic Escherichia coli. Afr J Plant Sci 2009, 3(2):025-029.
• [19]Badmaev V, Nowakowski M: Protection of epithelial cells against influenza A virus by a plant derived biological response modifier ledretan-96. Phytother Res 2000, 14:245-249.
• [20]World Health Organization: Manual on Animal Influenza Diagnosis and Surveillance. Switzerland, Geneva: WHO Department of Communicable Diseases Surveillance and Control; 2002. WHO/CDS/CSR/NCS/WHO: 2002:1–98. 5 Rev
• [21]Gaush CR, Smith TF: Replication and plaque assay of influenza virus in an established line of canine kidney cells. Appl Microbiol 1968, 16(4):588-594.
• [22]Payungporn S, Phakdeewirot P, Chutinimitkul S, Theamboonlers A, Keawcharoen J, Oraveerakul K, Amonsin A, Poovorawan Y: Single-step multiplex reverse transcription-polymerase chain reaction (RT-PCR) for influenza A virus subtype H5N1 detection. Viral Immunol 2004, 17(4):588-93.
• [23]Tsukamoto K, Ashizawa H, Nakanishi K, Kaji N, Suzuki K, Okamatsu M, Yamaguchi S, Mase M: Subtyping of H1 to H15 hemagglutinin genes of avian influenza virus by RT-PCR assay 4 and molecular determination of the pathogenic potential. J Clin Microbiol 2008, 46(9):3048-55.
• [24]World Health Organization: A revision of the system of nomenclature for influenza viruses: a WHO Memorandum. Bull World Health Org 1980, 58(4):585-591.
• [25]Hoffmann E, Stech J, Guan Y, Webster RG, Perez DR: Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol 2001, 146(12):2275-89.
• [26]Tamura K, Nei M: Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. Mol Biol Evol 1993, 10:512-526.
• [27]Hour MJ, Huang SH, Chang CY, Lin YK, Wang CY, Chang YS, Lin CW: Baicalein, ethyl acetate, and chloroform extracts of Scutellaria baicalensis inhibit the neuraminidase activity of pandemic 2009 H1N1 and seasonal influenza A viruses. Evid Based Complement Alternat Med 2013, 2013:750803. doi:10.1155/2013/750803
• [28]Khesorn N, Patoomratana T: Antimicrobial activity of hexane and dichloromethane extracts from Momordica cochinchinensis (Lour.) Spreng Leaves. Thai Pharm Health Sci J 2009, 4:15-20.